1. Introduction {#s0005}
===============

There has been a significant increase in the number of patients receiving cardiovascular implantable electronic devices (CIED) over the last two decades [@bib1], [@bib2]. This is largely owing to the expanding indications of CIED based on technological improvements and new evidence demonstrating improved survival and quality of life among certain groups of patients having structural heart diseases [@bib3], [@bib4]. However, the advantage of these devices is limited by associated adverse events and complications. CIED infection represents a serious complication of cardiac device therapy and is associated with significant morbidity and mortality. Despite appropriate care, in-hospital mortality among patients admitted because of CIED infection ranges from 4% to 10% and one-year mortality from 15% to 20% [@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11].

The majority of patients with CIED infection have pocket and/or endovascular lesions ([Fig. 1](#f0005){ref-type="fig"}). If aggressive antibiotic therapy fails to control CIED infection, then complete removal of the device is recommended in many instances [@bib2], [@bib6]. The timing of re-implantation is another critical issue. An early re-implantation should be performed in patients who are solely dependent on the CIED; however, at least one week is required to control local or systemic bacterial infections [@bib12]. Currently, the advanced technologies may contribute to a decrease in infection risk and mortality and may bridge the critical period between device removal and re-implantation.

2. New technologies to reduce the risk of CIED infection {#s0010}
========================================================

In the USA and Europe, some new alternatives to prevent CIED infection are available. The leadless pacemaker and antibacterial envelope represent attractive and suitable therapeutic options to minimize the risk of CIED infection.

2.1. Leadless pacemaker {#s0015}
-----------------------

To reduce the complications associated with the standard transvenous electrode lead of the pacemaker, a leadless pacemaker has been invented. The concept of a completely self-contained VVIR intracardiac pacemaker, first explored about 45 years ago by Spickler JW et al., has finally become a reality with the development of the Nanostim™ Leadless Pacemaker (St Jude Medical, Inc., St. Paul, MN, USA) and the Micra™ Transcatheter Pacing System (Medtronic plc) for use in humans [@bib13], [@bib14], [@bib15], [@bib16]. Technological advances in electronics miniaturization and battery chemistries have enabled creation of a device small enough to be implanted within the heart via a percutaneous, transvenous approach, while still providing similar battery longevity without leads. The leadless pacemaker has been expected to reduce CIED infections, because this system has no physical connection between the endocardium and the subcutaneous pocket, which are the most likely source and channel of bacterial infection, respectively. Furthermore the leadless stand-alone system never produces subclavian or supra vena-cava occlusions. Both systems have received the CE Mark in Europe, but are not approved in the USA.

The Nanostim system is delivered to the implant site at the lower septum of the right ventricle (RV) via a transfemoral route and allows for bradycardia pacing via a miniature pulse generator with a built-in battery and electrodes that can be entirely and permanently implanted ([Fig. 2](#f0010){ref-type="fig"}). The first successful Nanostim implantation in humans took place in December 2012 in Prague, Czech Republic. Recently, a nonrandomized first-in-human study demonstrated this system to be safe and feasible over a 90-day period [@bib15]. This preclinical study expanded on the previous study by demonstrating that the pacing and sensing properties remain adequate for up to 18 months. In addition, the histological analyses at the 90-day mark revealed a limited local response to the implanted device at the RV apex. Furthermore, there were no significant adhesions between the device and the RV walls. These pathological features may have important implications related to the long-term efficacy and safety of this system, as well as for designing approaches to extract the device.

The Micra system, similar to the Nanostim system, is an investigational device and is being assessed in a pivotal global clinical trial. The miniaturized device is only one-tenth the size of a conventional pacemaker ([Fig. 3](#f0015){ref-type="fig"}). The Micra system is also delivered directly into the heart through a catheter inserted in the femoral vein. Once positioned, the pacemaker is securely attached to the heart wall in the RV and can be repositioned or retrieved during implantation if needed ([Fig. 4](#f0020){ref-type="fig"}). The device does not require the use of leads and is attached via small tines securing it to the heart wall. The first successful in-human Micra implantation occurred in December 2013 in Linz, Austria. It is currently being evaluated in the Medtronic Micra Transcatheter Pacing System (TPS) Global Clinical Trial, which is a single-arm, multicenter study that will enroll up to 780 patients at approximately 50 centers [@bib16].

Both systems allow for retrievability, if needed; however, there are significant differences in the designs that are worth noting: (i) the Micra device has an active fixation mechanism consisting of four electrically-inactive extendable and retractable tines to anchor it to the cardiac tissue, whereas the Nanostim device uses an electrically active fixed helix, (ii) the Micra device is wider (20 Fr) and shorter (25.9 mm) than the Nanostim pacemaker (18 Fr and 41.4 mm), (iii) the Micra pacemaker׳s communication between the device and programmer is established using a standard programming head, whereas the Nanostim pacemaker communicates with the St. Jude Medical Merlin™ Patient Care System using a programmer link and surface electrocardiographic electrodes, and (iv) the Micra device uses a three-axis accelerometer for rate response, whereas the Nanostim pacemaker utilizes a blood temperature sensor.

The most relevant limitation is that the current Nanostim and Micra devices are indicated for patients requiring a single-chamber pacemaker only, limiting their use to a relatively small percentage of patients. Current indications focus on patients with chronic atrial fibrillation and second- or third-degree atrioventricular block, patients with sinus rhythm with second- or third-degree atrioventricular block and a low level of physical activity or short expected lifespan, and patients with sinus bradycardia with infrequent pauses or unexplained syncope.

2.2. Anti-bacterial envelope {#s0020}
----------------------------

Previously published randomized controlled studies indicate that perioperative intravenous administration of a cephalosporin antibiotic can help to reduce CIED infections [@bib2], [@bib18]. The European Society of Cardiology, American Heart Association, and Heart Rhythm Society recommendations for prophylaxis at the time of CIED placement consist of an antibiotic that has in-vitro activity against staphylococci. In recent large studies, the vast majority of patients received antimicrobial prophylaxis with CIED placement [@bib19], [@bib20]. Despite widespread use of antimicrobial prophylaxis, CIED infection rates are increasing faster than implantation rates [@bib21]. Effective antimicrobial prophylaxis could help reduce CIED infections and improve clinical outcomes.

The TYRX™ Antibacterial Envelope (Medtronic plc) consists of a Food and Drug Administration (FDA)-approved surgical mesh envelope that releases minocycline and rifampicin in the generator pocket after implantation with a CIED ([Fig. 5](#f0025){ref-type="fig"}) [@bib17]. The biocompatible mesh is coated with antibiotics that elute (dissolve) within an approximately 7-day period. The TYRX™ is of two types, with substrate meshes that are 100% absorbable or non-absorbable. A recent report suggests that the use of the TYRX™ absorbable envelope was associated with a very low prevalence (0%) of CIED-related infections that was comparable to that seen with the non-absorbable envelope. However, data from a randomized clinical trial are needed to support increased use of the antibacterial envelope [@bib22]. Both TYRX™ Antibacterial Envelopes are sterile devices constructed of an open-pore weave, knitted filaments of a lightweight mesh, and an absorbable polymer coating impregnated with antimicrobial agents. The antibacterial envelope is indicated for holding CIEDs, thereby creating a stable environment surrounding the device and leads after surgical placement.

At least one-half to two-thirds of CIED infections are caused by *Staphylococcus aureus* (*S. aureus*) and coagulase-negative staphylococcus species (CoNS) [@bib18], [@bib20], [@bib23], [@bib24], [@bib25]. In vitro, methicillin-resistant strains of *S. aureus* and many strains of CoNS are susceptible to a combination of two antibiotics with distinct mechanisms of actions: minocycline and rifampicin [@bib26], [@bib27], [@bib28]. Rifampicin is bacteriostatic and inhibits DNA-dependent RNA polymerase. Minocycline is bacteriostatic and inhibits protein synthesis. Minocycline has an antimicrobial spectrum against a wide range of gram-positive and gram-negative organisms. Rifampin is a semi-synthetic compound derived from *Amycolatopsis rifamcinica* and has antimicrobial activity against select gram-positive and gram-negative organisms. The substrate mesh varies between the two types of envelopes and consists of either polypropylene or Glycoprene II. Polypropylene has been utilized in surgically implanted medical devices for decades. The most common use is in hernia repairs.

The absorbable tyrosine-based polymer coating is designed to degrade to well-characterized natural metabolites. It has been demonstrated to resorb benignly, in the same manner as absorbable surgical sutures, while eliciting a minimal inflammatory response. It also has a long history of use with other FDA-approved implantable medical devices. Randomized controlled trials demonstrated that coating or impregnating catheters with the combination of rifampin and minocycline significantly reduces device-associated infections of central venous, hemodialysis, and cerebrospinal fluid drain catheters, especially infections with *S. aureus* and CoNS [@bib29], [@bib30], [@bib31], [@bib32], [@bib33], [@bib34], [@bib35].

Preclinical studies demonstrated that the antibacterial envelope helped reduce the risk for infection by several pathogens, including *Staphylococcus epidermidis*, within CIED implant pockets [@bib36]. A previous large clinical study indicated that the envelope is associated with a high rate of successful CIED implantation and a low risk of infection in a population at significant risk for CIED infection. Furthermore, standard use of an antibacterial envelope was associated with a significantly lower rate of CIED infection and appeared to be economically viable [@bib37].

3. New technology for prevention of fatal CIED infection {#s0025}
========================================================

It is widely accepted that complication rates are higher with re-implantations, particularly if a lead implantation or revision is involved [@bib38], [@bib39]. In addition, morbidity and mortality is particularly high in patients with an infected transvenous implantable cardioverter defibrillator (transvenous-ICD) system, especially when a systemic infection or endocarditis is present.

The risk of reinfection following system re-implantation is also a concern [@bib40], [@bib41].

A completely subcutaneous ICD was developed as an alternative to the transvenous-ICD system, as it is implanted without any transvenous or epicardial leads. The rate of infections resulting in explantation or revision of this new device was not lower than that reported in previous ICD registries. However, it should be emphasized that none of the documented device infections were systemic [@bib42].

3.1. Complete subcutaneous implantable cardioverter defibrillator {#s0030}
-----------------------------------------------------------------

The completely subcutaneous ICD system (S-ICD™ System, Boston Scientific Corp., Marlborough, MA, USA) was developed to provide life-saving defibrillation therapy while leaving the heart and vasculature untouched [@bib43]. The S-ICD system is preferred over transvenous-ICD for patients having no vascular access, a history of recurrent transvenous lead infections, or primary electrical disease with ventricular fibrillation as the major life-threatening rhythm. The first pilot-phase human studies of the S-ICD commenced in 2008, followed by subsequent regulatory and post-marketing studies. Approved by the FDA in September 2012, to provide defibrillation therapy for the treatment of ventricular tachyarrhythmias, the S-ICD system was developed after 10 years of defibrillation and sensing research, acute human feasibility studies, and long-term clinical studies [@bib43], [@bib44], [@bib45], [@bib46], [@bib47], [@bib48], [@bib49]. This system demonstrated a very high shock efficacy for spontaneous ventricular arrhythmias and a decreased incidence of inappropriate shocks [@bib48].

The S-ICD system is comprised of a pulse generator, subcutaneous electrode, electrode-insertion tool, and device programmer. The pulse generator has an estimated longevity of 5 years and is slightly larger with a weight (145 g) approximately double that of a modern transvenous ICD generator [@bib49]. It provides high-energy defibrillation shock (80 J) therapy through the use of a constant-tilt biphasic form. In addition, the new generation S-ICD System (EMBLEM™ \[[Fig. 6](#f0030){ref-type="fig"}\]), which is 20% thinner and is projected to last 40% longer than the previous S-ICD system, is available in a small number of centers in Europe and USA. This system is also enabled for remote patient management for increased patient convenience. The generator is placed subcutaneously in a left lateral position over the 6^th^ rib between the midaxillary and anterior axillary lines. Via two parasternal incisions, a 3 mm tripolar parasternal electrode (polycarbonate urethane) is positioned parallel to and 1 to 2 cm to the left of the sternal midline with the distal sensing electrode localized adjacent to the manubriosternal junction and the proximal sensing electrode positioned adjacent to the xiphoid process ([Fig. 7](#f0035){ref-type="fig"}).

A population-based decrease in mortality with a new device is paramount, but can be negated if the implant is associated with a higher risk of removal due to pocket infection. Infection without any bacteremia remained the most common complication requiring invasive action in the early experience with the S-ICD [@bib44], [@bib45], [@bib46]. Many steps were taken to mitigate this risk and prevent device removal, including better operative preparation training and techniques and aggressive management of skin infections [@bib45]. Advances in implantation techniques were introduced in the literature by Knops et al. in an effort to reduce the incisional surface area and resulting infection risk [@bib50]. Advances in operator experience, preparation, and implantation techniques appear to have positively affected the rates of infection, as use of the S-ICD system has expanded worldwide. In recent studies, the simplicity of implantation which avoids vascular access was reflected in the very low rate (2%) of acute major complications such as device system infection [@bib48]. The S-ICD could be a new alternative to the conventional transvenous-ICD system to minimize device system infections.

The limitations of the current S-ICD include its inability to provide anti-tachycardia pacing for ventricular tachycardia, limited bradycardia pacing support, and absence of endovascular monitoring capabilities for collateral data gathering such as impedance monitoring for chronic heart failure. One estimate of potential candidates for the S-ICD includes every patient indicated for primary SCD prevention without a pacing indication. In addition, the use of a subcutaneous sensing electrode with the S-ICD may theoretically increase the risk of over-sensing noise or myopotential signals and under-sensing low-amplitude cardiac signals during ventricular fibrillation. The previous trial compared the arrhythmia detection of 3 commercially available transvenous ICD lead systems with the S-ICD electrode [@bib51]. All devices excelled in detecting ventricular tachyarrhythmia (100%); however, the S-ICD demonstrated greater specificity in discriminating supraventricular from ventricular tachycardia (98% S-ICD vs. 76.7% single-chamber transvenous-ICD vs. 68% dual-chamber transvenous-ICD). Ideally, greater user programming experience and improvements in S-ICD technology may reduce the rate of inappropriate shocks.

4. New technology to reduce the risk of sudden cardiac death after the removal of ICD: a wearable cardioverter defibrillator {#s0035}
============================================================================================================================

ICD therapy has been established as a cornerstone of cardiology practice for reducing the incidence of SCD [@bib52], [@bib53], [@bib54], [@bib55]. Unfortunately, ICD system infection represents a complication that occurs even in experienced centers. Among patients who require ICD removal and subsequent antibiotic therapy, a wearable cardioverter defibrillator (WCD; LifeVest WCD4000, ZOLL, Pittsburgh, PA, USA) represents an alternative approach to prevention of SCD. Removal of the ICD deprives the patient of the protection against potential life-threatening ventricular tachyarrhythmias, particularly in patients with ICD implantation for secondary prevention of SCD. The Heart Rhythm Society recommends the use of WCD as a bridge to ICD re-implantation when the ongoing infection is a concern [@bib56].

The WCD was introduced into clinical practice in 2002, and indications for its use are expanding currently. It has been in use worldwide, especially in the USA and Germany [@bib57], [@bib58].

This device consists of an external defibrillator vest that automatically detects and treats ventricular tachyarrhythmias without bystander assistance [@bib59], [@bib60]. A WCD is composed of a garment containing two defibrillation patch electrodes on the back, an elastic belt with a front-defibrillation patch electrode, and four non-adhesive ECG electrodes connected to a monitoring and defibrillation unit ([Fig. 8](#f0040){ref-type="fig"}). Recent trials demonstrated the efficacy of the WCD in the detection and treatment of lethal ventricular arrhythmias [@bib57], [@bib61]. The WCD therapy can prevent SCD until ICD re-implantation is feasible in patients who underwent device removals for device system infections [@bib62].

The efficacy of the WCD in the prevention of arrhythmic SCD would seem to be highly dependent on patient compliance. Proper instruction on the use of WCD is also important to avoid inappropriate shocks. In previous studies, inappropriate shock is a rare event that occurs in 0--3% of patients using WCD [@bib63], [@bib64]. Shocks may be inappropriately delivered due to noise, device malfunction, or the rate criteria. A WCD is a unique tool designed to avoid unnecessary shock therapy. If a persistent arrhythmia is detected, the WCD notifies the patient via a "responsiveness test," allowing a conscious patient to prevent treatment. A conscious patient can hold the "response buttons" during the "responsiveness test" to prevent an unnecessary treatment. Therefore, much attention is being paid to the provision of medical education and information to patients in order to optimize their understanding and acceptance of the WCD therapy [@bib59].

The strategy for re-implantation after removal of an ICD must be individualized to each patient and clinical situation. For many patients, continuous inpatient/outpatient monitoring may be impossible or at least highly undesirable. The WCD is a cost-effective alternative to protect patients against SCD following the removal of an infected ICD while waiting for ICD re-implantation, as compared to keeping patients in the hospital or discharging them to go home or to a skilled nursing facility [@bib12].

5. Conclusion {#s0040}
=============

CIED system infection represents a relevant complication after CIED implantation and is associated with a significant risk of morbidity and mortality. However, newly developed technologies and devices represent attractive and suitable therapeutic options to reduce the incidence of this increasing problem.
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